The cancellation of 36 certification items affected many medical personnel

On April 28, the State Administration of Pharmaceutical Supervision issued the Notice on the Cancellation of 36 Certificates (No. 34, 2019). The State Drug Administration has decided to cancel 36 certification items in accordance with the requirements of the Notice of the General Office of the State Council on Cleaning up Certificate Matters, in order to further reduce certification for the convenience of the people and optimize services.
Since the date of publication, the certification items set forth in the normative documents listed in the Annex have ceased to be executed. If the certification matters set forth in the regulations of the departments listed in the annex involve revision of the rules of the departments, the implementation of the rules shall be stopped after revision of the rules of the departments according to the procedures. 36 items of certification include 14 items of "certification matters for the establishment of normative documents" and 24 items of "certification matters for the establishment of departmental regulations". Many things, no longer require applicants to submit this, instead of network verification. It involves many aspects, such as drug production license, licensed pharmacist registration certificate and so on.
2026-09-28
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
India Proposes New GMP Rules for Clinical Trial and API Manufacturing
-
India's PV Community Comes Together at the 6th Edition Drug Safety Symposium 2026 – India Chapter to Shape the Future of Patient Safety
-
6th Drug Safety Symposium 2026 to Focus on “Beyond Algorithms & Assumptions, What Actually Matters in Pharmacovigilance”
-
Roche Acquires Carmot for $3.1 Billion to Enter Obesity Drug Market
-
Two departments issued a document to guidethe strengthening of drug cases investigation and handling
-
National Health Care Commission: 50% of thecountry's public hospitals above the second level have carried out appointmentdiagnosis and treatment services
-
India starts testing a pharmaceuticalcompany's exports of cough syrup
-
Inmanar Announces Several BreakthroughSequencing Innovations
-
China's medical supplies supply securitycapabilities continue to enhance
-
244 medical device concept stocks roseindustry insiders said the process of domestic replacement is expected toaccelerate
Recommend Reading
-
Wuxi Yinda Nylon Acquires German Century-Old Chemical Giant Perlon
-
Another Major Coating Manufacturer Acquired by a Central SOE: BNBM Acquires SUNROAD Group for Over RMB 300 Million, Locks in Three-Year Performance Pledge
-
Behind Arkema’s ¥430 Million Claim: A Patent War Over Acrylic Acid Is Tearing Off the “Technical Fig Leaf” of China’s Chemical Giants
-
US Imposes Heavy Duties on Chinese L-Lysine with Combined Rates up to 188%
-
Korea’s First Petrochemical Restructuring Approved, LDPE Market Concentration Surges to 82%
-
Business Society’s EVA Market Outlook on August 11, 2026: Short-Term Price Decline
-
Premium Global Chemical Sourcing Requests (18-21Jun, 2026)
-
Premium Global Chemical Sourcing Requests (25-28Jun, 2026)
-
Business Society’s Market Outlook for MIBK on August 11, 2026: Tending to Weak
-
Lido Still Active, Palm Oil Prices Fluctuate and Rise